| Field | Specification |
|---|---|
| Target | |
| Alternative names | Transient receptor potential cation channel subfamily M member 4;hTRPM4;Calcium-activated non-selective cation channel 1;Long transient receptor potential channel 4;LTrpC-4;LTrpC4;Melastatin-4;TRPM4;LTRPC4; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human TRPM4 recombinant protein (Position: F1079-D1214). Human TRPM4 shares 76.8% and 77.8% amino acid (aa) sequence identity with mouse and rat TRPM4, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes transient receptor potential cation channel subfamily M member 4 (gene TRPM4) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 134.3 kDa, and the supplier reports an observed band at about 167 kDa.
TRPM4 is a calcium-activated channel that passes monovalent cations such as sodium but is not permeable to calcium itself. By depolarizing the membrane when intracellular calcium rises, it shapes electrical activity in heart muscle, neurons, smooth muscle and pancreatic β cells and tunes calcium oscillations in activated T cells; variants are known in inherited cardiac conduction disease.
| Target | Transient receptor potential cation channel subfamily M member 4 (gene TRPM4; UniProt Q8TD43, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 134.3 kDa |
| Observed MW | 167 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human prostate cancer tissue, human squamous cells carcinoma of cervix tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Recombinant human TRPM4 fragment (Phe1079–Asp1214), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 76.8% and 77.8%, respectively.
Reactivity Notes
The supplier lists reactivity with human. Tissue expression noted by UniProt (human): Widely expressed with a high expression in intestine and prostate. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
